Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Arvinas (NASDAQ:ARVN) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other equities analysts also recently issued research reports about the company. Barclays boosted their target price on Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Citigroup lifted their price target on Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Stephens reissued an “overweight” rating and issued a $18.00 price objective on shares of Arvinas in a research report on Wednesday, June 3rd. Zacks Research upgraded Arvinas from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Wedbush raised their target price on Arvinas from $11.00 to $12.00 and gave the company a “neutral” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $14.90.

Arvinas Price Performance

ARVN opened at $8.75 on Friday. The company’s 50-day moving average is $8.05 and its 200 day moving average is $10.24. Arvinas has a fifty-two week low of $6.09 and a fifty-two week high of $14.51. The firm has a market capitalization of $564.56 million, a P/E ratio of 87.51 and a beta of 1.71.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95. The business had revenue of $249.70 million during the quarter, compared to the consensus estimate of $60.71 million. Arvinas had a net margin of 2.94% and a return on equity of 1.91%. The firm’s quarterly revenue was up 1014.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.84) EPS. On average, equities research analysts expect that Arvinas will post -1.15 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Randy Teel sold 9,657 shares of Arvinas stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $95,990.58. Following the sale, the chief executive officer owned 287,218 shares of the company’s stock, valued at approximately $2,854,946.92. The trade was a 3.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Noah Berkowitz sold 11,108 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,413.52. Following the transaction, the insider directly owned 191,395 shares of the company’s stock, valued at approximately $1,902,466.30. This trade represents a 5.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 41,728 shares of company stock valued at $402,649. 7.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arvinas

Several large investors have recently added to or reduced their stakes in the company. Hussman Strategic Advisors Inc. purchased a new stake in Arvinas during the fourth quarter valued at about $1,245,000. Brummer Multi Strategy AB purchased a new position in shares of Arvinas in the fourth quarter worth about $1,973,000. VIRGINIA RETIREMENT SYSTEMS ET Al raised its position in shares of Arvinas by 371.0% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 70,650 shares of the company’s stock valued at $838,000 after purchasing an additional 55,650 shares during the period. Armistice Capital LLC raised its position in shares of Arvinas by 50.0% in the fourth quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock valued at $21,348,000 after purchasing an additional 600,000 shares during the period. Finally, Public Employees Retirement System of Ohio lifted its stake in shares of Arvinas by 876.1% during the 1st quarter. Public Employees Retirement System of Ohio now owns 97,611 shares of the company’s stock valued at $1,035,000 after buying an additional 87,611 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Zacks upgraded Arvinas to “Strong Buy.” The firm’s Zacks Rank #1 reflects improving expectations for the company’s earnings outlook and could support further buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: Arvinas reported a major quarterly earnings and revenue beat. Adjusted earnings were $2.58 per share versus the consensus estimate of a $0.37 loss, while revenue reached $249.7 million compared with expectations of $60.7 million. The sharp year-over-year revenue increase provides a fundamental reason for the recent rise in the shares. Arvinas Trading Higher on Strong Earnings
• Positive Sentiment: HC Wainwright raised several longer-term EPS estimates. The firm improved its forecasts for fiscal 2026 through 2029 and moved its fiscal 2030 outlook to a profit of $0.07 per share from a projected loss, suggesting better long-term operating prospects.
• Neutral Sentiment: Analyst opinions remain divided. BTIG maintained a Buy rating, while Wells Fargo lowered its rating to Equal Weight, limiting the impact of the bullish Zacks call. Arvinas Earns Buy Rating from BTIG Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: HC Wainwright cut its near-term earnings forecasts. Q3 2026 EPS was reduced to a loss of $1.20 from $1.02, and Q4 EPS to a loss of $1.19 from $1.02. The revisions reinforce expectations for continued losses and may weigh on the stock.
• Negative Sentiment: A recent analyst downgrade pressured the shares. The downgrade adds caution after the earnings-driven advance, particularly given Arvinas’ projected full-year loss and its position below the 200-day moving average. Arvinas Shares Down on Analyst Downgrade

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.